← Back to Search

Monoclonal Antibodies

Aflibercept 2.0mg for Retinal Vein Occlusion

Phase 4
Waitlist Available
Led By Franco M Recchia, MD
Research Sponsored by Tennessee Retina
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 6
Awards & highlights

Study Summary

The purpose of this study is determine the number of patients with complete resolution of macular edema secondary to central retinal vein occlusion following 6 monthly injections of Aflibercept.

Eligible Conditions
  • Retinal Vein Occlusion

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Complete anatomic resolution of macular edema following central retinal vein occlusion (CRVO) as measured by Optical Coherence Tomography (OCT)
Secondary outcome measures
Extent of reduction in macular thickness
Extent of reduction in macular volume
Mean change in best-corrected visual acuity (BCVA)
+2 more
Other outcome measures
Effect on macular leakage using fluorescein angiogram (FA)
Effect on peripheral retinal non-perfusion

Side effects data

From 2015 Phase 4 trial • 26 Patients • NCT01617148
4%
Cataract progression
100%
80%
60%
40%
20%
0%
Study treatment Arm
Single Group

Trial Design

1Treatment groups
Experimental Treatment
Group I: Aflibercept 2.0mgExperimental Treatment1 Intervention
Single arm - Intravitreal Aflibercept 2.0mg, 0.05 milliliters, monthly for 6 months.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Aflibercept
FDA approved

Find a Location

Who is running the clinical trial?

Tennessee RetinaLead Sponsor
2 Previous Clinical Trials
52 Total Patients Enrolled
Regeneron PharmaceuticalsIndustry Sponsor
622 Previous Clinical Trials
380,721 Total Patients Enrolled
11 Trials studying Retinal Vein Occlusion
4,537 Patients Enrolled for Retinal Vein Occlusion
Franco M Recchia, MDPrincipal InvestigatorTennessee Retina, PC

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy
2013. "Study of Intravitreal Aflibercept Injection for Persistent CRVO-associated Macular Edema Despite Prior Anti-VEGF Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01857544.
All > Macular Edema
~1 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top